Gemfibrozil alters lipid metabolism to treat patients with hyperlipidemia. 11 The duration of action requires twice daily dosing as the mean residence time of gemfibrozil is up to 9.6h in patients …

Gemfibrozil significantly increased plasma HDL cholesterol, apolipoprotein (apo) AI, and apo AII by 36%, 29%, and 38% from base line, respectively. Plasma TG decreased by 54%. Kinetics …

Here, we characterized the transporter-mediated hepatic disposition of GEM and GG using sandwich-cultured human hepatocytes (SCHH) and transporter-transfect systems. Significant …

Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating peroxisome proliferator-activated …

2022年6月28日 · Gemfibrozil (GEM), a lipid regulator, is a fibric acid derivative widely used in the treatment of hyperlipidemia. It has been reported that GEM can induce acute liver injury in the …

Gemfibrozil more potently inhibits CYP2C9 than CYP2C8 in vitro, and yet the opposite inhibitory potency is observed in the clinic. To investigate this apparent paradox, we evaluated both …

2005年10月11日 · Gemfibrozil (600 mg b.i.d. for 8 days) was evaluated for its ability to inhibit the CYP2C9-dependent metabolism of warfarin (because CYP2C9 is the enzyme most potently …

2010年10月4日 · Gemfibrozil produced alterations of lipid metabolism in each species; the effects and rats and mice were similar and distinct from hamsters. It is clear from several investigators …

1976年2月1日 · Gemfibrozil is a fibrate drug widely used for dyslipidemia associated with atherosclerosis. Clinically, both gemfibrozil and its phase II metabolite gemfibrozil1-O-β …

Gemfibrozil, a fibric acid derivative, is a widely used lipid-lowering drug. Its pharmacological effect seems to be based on reduction of VLDL synthesis and increase of VLDL catabolism. To test …